Rejuvenate Bio Multi-Gene Cocktail — Gene Therapy & Genetic Interventions
Combinatorial AAV gene therapy targeting multiple aging pathways simultaneously for synergistic lifespan extension.
Overview
Rejuvenate Bio, co-founded by George Church, develops combinatorial gene therapy cocktails targeting multiple aging pathways simultaneously. Their approach uses AAV vectors to deliver combinations of longevity-associated genes including sTGFBR2 (TGF-beta inhibitor), FGF21, alpha-Klotho, and soluble ACE2. In aged mice, a triple combination (sTGFBR2 + FGF21 + aKlotho) reversed age-related heart failure, kidney failure, obesity, and diabetes, with improvements exceeding single-gene therapies. The company conducted what it describes as the first anti-aging gene therapy in dogs (2022).
Indications
- Multi-organ age-related decline
- Heart failure with preserved ejection fraction (HFpEF)
- Age-related kidney disease
- Metabolic dysfunction and obesity
- Whole-organism rejuvenation
Mechanism of Action
Multiple AAV vectors simultaneously deliver longevity genes to target organs via IV infusion
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| AAV-sTGFBR2 + FGF21 + aKlotho | 1 x 10^12 vg/kg per vector | Single infusion | Triple combination; preclinical murine dosing |
Evidence Grade
GRADE C
Safety & Contraindications
- Multi-gene delivery increases complexity and potential for gene-gene interactions
- High-dose AAV hepatotoxicity risk
- Each transgene carries individual safety considerations
- TGF-beta pathway inhibition may impair wound healing and immune regulation
- Canine trial results not published in peer-reviewed literature
- No human clinical trials initiated